Stocktoria
COMPUGEN LTD CGEN
COMPUGEN LTD (CGEN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $72.8M at a 48.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.801 |
| Retained earnings / assets | -2.896 |
| EBIT / assets | 0.2 |
| Equity / liabilities | 1.908 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CGEN | COMPUGEN LTD | 6/9 | -0.84 | 5.6 | +161.1% |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 3/9 | -1.13 | — | +26.9% |
| AUTL | Autolus Therapeutics plc | 2/9 | -6.27 | — | +644.9% |
| BDTX | Black Diamond Therapeutics, Inc. | 6/9 | -0.83 | 4.4 | — |
| VIR | Vir Biotechnology, Inc. | 2/9 | -0.97 | — | -7.6% |
| MGTX | MeiraGTx Holdings plc | 2/9 | -14.65 | — | +144.6% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
About COMPUGEN LTD
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
FAQ
Is CGEN financially healthy?
COMPUGEN LTD's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CGEN pay a dividend?
No, COMPUGEN LTD does not currently pay a dividend.
How profitable is CGEN?
In FY2025, COMPUGEN LTD had a net margin of 48.6% and a return on equity of 34.4%.
What is CGEN's P/E ratio?
COMPUGEN LTD's trailing price-to-earnings (P/E) ratio is about 5.6×, based on its latest annual earnings.
What is the analyst price target for CGEN?
The average Wall-Street price target for COMPUGEN LTD is $4.60, about 84.0% above the recent price, from 5 analysts.
Is CGEN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on COMPUGEN LTD: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 5.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.